Orgenesis Inc. appointed Chris Buyse as a board of directors. Mr. Prior to that, from 2006 to 2014, Mr. Buyse was Chief Financial Officer and Director of ThromboGenics NV. Before joining ThromboGenics, he was Chief Financial Officer of CropDesign, where he coordinated its acquisition by BASF in July 2006.

Prior to joining CropDesign, Mr. Buyse served as finance manager at WorldCom/MCI Belux, and Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies. In addition, Mr. Buyse has held various positions in finance at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever. Chris Buyse is also currently a director in several private and public companies, such as Bone Therapeutics SA, Cardio 3 Biosciences SA, Iteos, SA and Bioxodes SA.